Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377234 | 0.88 | CCR9 (0.48) | CCR9HPGDKDM4EHSPA1APABPC1 | |
| SCHEMBL3376209 | 0.86 | CCR9 (0.46) | CCR9HPGDKDM4EHSPA1APABPC1 | |
| SCHEMBL3376147 | 0.86 | CCR9 (0.44) | CCR9HPGDKDM4EDRD2HSPA1A | |
| SCHEMBL3373168 | 0.84 | HPGD (0.41) | CCR9HPGDKDM4EDRD2HSPA1A | |
| SCHEMBL3373596 | 0.84 | DRD2 (0.43) | CCR9HPGDKDM4EDRD2HSPA1A | |
| SCHEMBL3377842 | 0.83 | LMNA (0.50) | CCR9DRD2ALDH1A1 | |
| SCHEMBL3376342 | 0.80 | CCR9 (0.47) | CCR9HPGDKDM4EHSPA1APABPC1 | |
| SCHEMBL4432198 | 0.79 | HSPA1A (0.61) | CCR9HPGDKDM4EHSPA1APABPC1 | |
| SCHEMBL4419914 | 0.78 | CCR9 (0.47) | CCR9HPGDKDM4EHSPA1APABPC1 | |
| SCHEMBL30758589 | 0.77 | KMT2A (0.57) | KDM4EKMT2AALDH1A1PGRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517886-B1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7132455-B2 | Phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20060035967-A1 | Novel phthalamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| EP-1517886-A1 | NOVEL PHTHALAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000796-A1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035967-A1 | Novel phthalamide derivatives | HDAC1, HDAC2, CRY1 | CCR9 4535/4885HPGD 2293/4885KDM4E 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.